Last reviewed · How we verify

DX-2930 — Competitive Intelligence Brief

DX-2930 (DX-2930) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Factor XIIa inhibitor. Area: Cardiovascular.

phase 3 Factor XIIa inhibitor Factor XIIa (FXIIa) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

DX-2930 (DX-2930) — Shire. DX-2930 is a Factor XIIa inhibitor that reduces contact pathway activation to prevent thrombosis without affecting primary hemostasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DX-2930 TARGET DX-2930 Shire phase 3 Factor XIIa inhibitor Factor XIIa (FXIIa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Factor XIIa inhibitor class)

  1. Shire · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DX-2930 — Competitive Intelligence Brief. https://druglandscape.com/ci/dx-2930. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: